Abstract
The creation of commercial cord blood banks rests on the promise of stem cell based regenerative medicine and marks the capitalization of human tissues within a future-oriented ?regime of hope?. This paper will present data from a survey of the international cord blood banking industry and will explore: (a) the way firms seek to commercialize cord blood as a new set of commodities; (b) the expectations and moral economy that are being constructed around this technology; and (c) how firms are acting as mediators of hope in what might be called a ?promissory bioeconomy?.
| Original language | English |
|---|---|
| Pages (from-to) | 127-143 |
| Number of pages | 17 |
| Journal | New Genetics and Society |
| Volume | 27 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2008 |